Thyrocare Technologies (NSE:THYROCARE) Debt-to-Equity : 0.08 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Thyrocare Technologies Debt-to-Equity?

Thyrocare Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹196 Mil. Thyrocare Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹227 Mil. Thyrocare Technologies's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹5,268 Mil. Thyrocare Technologies's debt to equity for the quarter that ended in Mar. 2024 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Thyrocare Technologies's Debt-to-Equity or its related term are showing as below:

NSE:THYROCARE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 0.08
Current: 0.08

During the past 10 years, the highest Debt-to-Equity Ratio of Thyrocare Technologies was 0.08. The lowest was 0.01. And the median was 0.03.

NSE:THYROCARE's Debt-to-Equity is ranked better than
75.65% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs NSE:THYROCARE: 0.08

Thyrocare Technologies Debt-to-Equity Historical Data

The historical data trend for Thyrocare Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thyrocare Technologies Debt-to-Equity Chart

Thyrocare Technologies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.02

0.04

0.08

Thyrocare Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.04	N/A	0.10	N/A	0.08

Competitive Comparison of Thyrocare Technologies's Debt-to-Equity

For the Diagnostics & Research subindustry, Thyrocare Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thyrocare Technologies's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Thyrocare Technologies's Debt-to-Equity falls into.

Thyrocare Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Thyrocare Technologies's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(196.3	+	227.1)	/	5267.7
	=	0.08

Thyrocare Technologies's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(196.3	+	227.1)	/	5267.7
	=	0.08

Thyrocare Technologies (NSE:THYROCARE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Thyrocare Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Thyrocare Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Thyrocare Technologies (NSE:THYROCARE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Thyrocare Technologies Ltd (NSE:THYROCARE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

539871:India

Address

D-37/1, TTC Industrial Area, MIDC, Turbhe, Opposite Sandoz, Navi Mumbai, MH, IND, 400703

Website

https://www.thyrocare.com

Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Other. The Diagnostic Testing Services segment provides a medical diagnostic investigation into thyroid disorders, metabolism disorders, diabetes, anemia, infertility, auto-immunity, and other infectious diseases. The company primarily earns majority of its revenue from Diagnostic Testing Services segment. The Imaging Services segment operates a network of imaging centers focused on early and effective cancer monitoring. The Other business segment provides miscellaneous services. The company earns the vast majority of its revenue in India.

Thyrocare Technologies (NSE:THYROCARE) Headlines

No Headlines